1.	Phase III Randomized Study of High Versus Standard Dose Methotrexate and High Dose Cytarabine and Asparaginase Rescue Versus Standard Dose Cytarabine and Teniposide During Intensive Continuation and Consolidation in Children with High Risk Acute Lymphocytic Leukemia: An ALinC #16 Study Phase: Phase III Type: Treatment Status: Closed Age: 1 to 21 at diagnosis Sponsor: NCI Protocol IDs: POG-9406, POG-ALINC-16/HR
2.	Phase III Randomized Study of Bone Marrow Transplantation vs Prolonged Intensive Chemotherapy Following Remission Re-Induction after Early First Marrow Relapse in Children with Acute Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: at least 1 + under 20 at diag. Sponsor: NCI Protocol IDs: CCG-1941
3.	Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 1 to 9 Sponsor: NCI, Other Protocol IDs: CDR0000064665, CCG-1952, NCT00002744
4.	Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 96-015, P30CA008748, MSKCC-96015A1, NCI-V96-0881, NCT00002766
5.	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000064953, CCG-1961, NCT00002812
6.	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: under 21 Sponsor: NCI, Other Protocol IDs: CDR0000064968, CCG-1951, NCT00002816
7.	Phase III Randomized Study of Prednisolone Versus Dexamethasone and Mercaptopurine Versus Thioguanine in Children With Acute Lymphoblastic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 1 to 18 Sponsor: Other Protocol IDs: MRC-LEUK-ALL97, EU-97032, NCT00003437
8.	Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 1 to 9 Sponsor: NCI, Other Protocol IDs: CDR0000067657, COG-P9904, POG-9904, NCT00005585
9.	Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 1 to 21 at diagnosis Sponsor: NCI, Other Protocol IDs: 9905, COG-P9905, POG-9905, CDR0000067704, NCI-2012-02325, NCT00005596
10.	Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 1 to 9 Sponsor: NCI, Other Protocol IDs: 1991, CCG-1991, CDR0000067855, NCI-2012-02333, U10CA98543, COG-C1991, NCT00005945
11.	Phase III Comparison of Intensification with MP/MTX vs Alternating MP/MTX, VM-26/ARA-C, and DNR/ARA-C/VCR/PRED/PEG-ASP Following Induction with PRED/VCR/ASP/DNR in Children with Higher-Risk ALL Phase: Phase III Type: Treatment Status: Closed Age: 12 months to 21 years Sponsor: NCI Protocol IDs: POG-9006
12.	Phase III Study of Varying Doses of DM, Conventional ASP vs PEG-ASP, Conventional vs High-Dose MP, Bolus vs Continuous Infusion DOX, and Conventional vs Hyperfractionated Cranial Irradiation in Children with ALL or Undifferentiated Leukemia Phase: Phase III Type: Treatment Status: Completed Age: under 18 Sponsor: NCI Protocol IDs: DFCI-91001, NCI-T91-0059D, T91-0059
13.	Pilot Phase III Study of Intensive High-Dose PEG-ASP in Combination Chemotherapy for T-Cell ALL and Lymphoblastic Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: under 22 Sponsor: NCI Protocol IDs: POG-9295
14.	Phase III Pilot Study of PRED/VCR/PEG-ASP followed by MTX/MP/CF in Standard-Risk Patients with Acute Lymphocytic Leukemia: Protocol ALinC #16 Phase: Phase III Type: Treatment Status: Closed Age: 1 to 21 years Sponsor: NCI Protocol IDs: POG-9202
15.	Pilot Phase III Study of Intensive Multiagent Consolidation with ID MTX/MP and ID MTX/ARA-C with Continuous Alternate-Week PEG-ASP in High-Risk Patients with ALL Phase: Phase III Type: Treatment Status: Completed Age: 12 months to 21 years Sponsor: NCI Protocol IDs: POG-9203
16.	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 1 to under 31 Sponsor: NCI, Other Protocol IDs: AALL0232, COG-AALL0232, CDR0000349182, NCT00075725
17.	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 1 to under 10 Sponsor: NCI, Other Protocol IDs: CDR0000409589, COG-AALL0331, AALL0331, NCT00103285
18.	Treatment of Acute Lymphoblastic Leukemia in Children Phase: Phase III Type: Treatment Status: Closed Age: 1 to 17 Sponsor: NCI, Other Protocol IDs: 05-001 / CDR0000513019, P01CA068484, P30CA006516, DFCI-05001, NCT00400946
19.	A Study of Actonel for the Prevention of Bone Loss Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: ID03-0124, NCT00452439
20.	Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 1 to 30 Sponsor: NCI Protocol IDs: NCI-2009-00312, AALL0622, CDR0000600217, COG-AALL0622, U10CA098543, NCT00720109
21.	Phase I/II Study of an "Up-Front" Therapeutic Window with 6-MP Followed by Intensified Systemic Induction, Consolidation, and Intensification with Intrathecal Therapy Followed by Delayed Craniospinal Irradiation in Children with Isolated CNS Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: over 1 to 21 Sponsor: NCI Protocol IDs: POG-9061
22.	Phase I/II Study of PEG-ASP (M) vs PEG-ASP (KH) in Patients with ALL, AUL, or NHL Who Are Hypersensitive to Native Escherichia coli and/or Erwinia L-ASP (Summary Last Modified 11/92) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: under 30 Sponsor: NCI Protocol IDs: ENZON-ASP-305, NCI-91-C-116, NCI-T91-0129N, T91-0129
23.	Phase I/II Pilot Study of MTX/PEG-ASP in Patients with Relapsed and Refractory Hematologic Malignancies (Summary Last Modified 09/93) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: ENZON-ASP-107, NCI-V93-0255
24.	Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 1 and under 21 Sponsor: Other Protocol IDs: T2005-003, NCT00440726
25.	Phase II Study of PEG-ASP in Adults with Refractory Chronic Lymphocytic Leukemia (Summary Last Modified 04/95) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: ENZON-ASP-210, NCI-V93-0341